This Natural Compound Combats Cancer – Scientists Have Finally Figured Out How

Trabectedin Graphic

Trabectedin, an anti-cancer drug originally isolated from the sea squirt Ecteinascidia turbitana, is known to form cytotoxic DNA adducts. It is used to treat sarcomas and ovarian cancers and, in contrast to most antitumor agents, exerts its full activity in cells with active DNA repair. Credit: Institute for Basic Science

Researchers have unlocked the method by which trabectedin circumvents the DNA repair mechanisms of cancer cells, paving the way for tailored treatments.

Many cancer treatments work by attacking the

Summary of the Mechanism of Trabectedin Induced TC NER Mediated Break Formation and Break Mapping by TRABI Seq

Summary of the mechanism of trabectedin-induced TC-NER-mediated break formation and break mapping by TRABI-Seq. Trabectedin-DNA adducts are recognized by TC-NER and lead to an abortive reaction as these adducts block the incision of the XPG endonuclease, causing persistent XPF-mediated breaks. TRABI-Seq (TRABectidin-Induced break sequencing) was used to map those breaks in a genome-wide fashion. The distribution of these persistent breaks was mostly ascribed to highly transcribed regions of the genome. This approach will now be used to determine how trabectedin induces DNA breaks in genomes of various cancer cell lines to develop TRABI-Seq as a diagnostic tool for cancer therapy. Credit: Institute for Basic Science

How Trabectedin Induces DNA Breaks in Cancer Cells

Using highly sensitive high throughput COMET Chip assays to detect breaks formed in the genomes of cells, IBS researchers revealed trabectedin induces persistent breaks in the DNA of cancer cells. The researchers showed that these DNA breaks are only formed in cells with high levels of DNA repair, specifically those that operate a pathway called transcription-coupled nucleotide excision repair (TC-NER).

TC-NER is a vital mechanism that identifies DNA damage during transcription, initiating repair processes involving two endonucleases ERCC1-XPF and XPG. Trabectedin’s DNA damage disrupts this process by allowing the initial incision by ERCC1-XPF but blocking the subsequent action by XPG, halting the TC-NER process. This disruption of the repair process leads to long-lasting DNA breaks that ultimately kill cancer cells.

COMET Chip Assays Were Used To Measure Trabectedin Induced Breaks in Cells

COMET Chip assays were used to measure Trabectedin-induced breaks in cells. Each green dot is a single nucleus of a cell and the tail length and the fraction of total DNA in the tail (comet) emerging from each nucleus is proportional to the number of breaks formed. Following UV treatment (left), few breaks are visible as UV lesions are excised from DNA by nucleotide excision repair (NER). Following treatment with trabectedin (center), DNA breaks persist due to an abortive NER reaction. The breaks are dependent on NER as they do not occur in TC-NER deficient cells (right) with inactivated XPF gene. Credit: Institute for Basic Science

Analysis of the DNA break patterns induced by trabectedin revealed that breaks are formed throughout the genome, but only at sites where active transcription and with it, TC-NER occurs. Using this new insight into the mechanism of how DNA breaks are accumulated, the researchers sought to determine where in the genome these breaks occur. This led to the development of a new method called TRABI-Seq (for TRABectedin-Induced break sequencing), which allows for the precise identification of trabectedin’s action sites within tumor cell DNA.

“This incision by ERCC1-XPF creates a markable free hydroxyl group in the DNA, enabling us to sequence DNA and locate these breaks,” explains Dr. Son.

TRABI-Seq is being tested on various cancer cells to determine trabectedin’s efficacy in targeting tumors with advanced DNA repair capabilities, often associated with elevated transcription levels due to oncogene activation. It is hoped that these findings will help position trabectedin as both a predictive marker to identify vulnerable cancers and a therapeutic option for precision treatment. With its ability to target tumors resistant to conventional therapies, trabectedin may provide further hope in the fight against drug-resistant cancer with highly active DNA repair capabilities.

Reference: “Trabectedin derails transcription-coupled nucleotide excision repair to induce DNA breaks in highly transcribed genes” by Kook Son, Vakil Takhaveev, Visesato Mor, Hobin Yu, Emma Dillier, Nicola Zilio, Nikolai J. L. Püllen, Dmitri Ivanov, Helle D. Ulrich, Shana J. Sturla and Orlando D. Schärer, 15 February 2024, DOI: 10.1038/s41467-024-45664-7

The study was funded by the Institute for Basic Science.

Institute for Basic Science
Read More

Latest

GloRilla And Megan Thee Stallion Have The Upper Hand In “Wanna Be” Music Video

Music Memphis’ and Houston’s finest have come together for...

Killer Mike, Doja Cat, Burna Boy And More Drop New Music Videos

MusicEvery day, artists update their releases with music...

Long after tonight is all over …

Music Take the floor: The dance area...

Newsletter

Don't miss

GloRilla And Megan Thee Stallion Have The Upper Hand In “Wanna Be” Music Video

Music Memphis’ and Houston’s finest have come together for...

Killer Mike, Doja Cat, Burna Boy And More Drop New Music Videos

MusicEvery day, artists update their releases with music...

Long after tonight is all over …

Music Take the floor: The dance area...

CMT Awards return Sunday night with host Kelsea Ballerini and a tribute to the late Toby Keith

Music Author of the article:The Associated PressMaria ShermanPublished Apr...

Want to succeed in business? Find a problem to solve | Anthony Tan and Amane Dannouni

Update requirements Looking for ted.com? v95+ v58+ v13+ v96+ v82+ Looks like your browser is out of date For questions contact us at support@ted.com

News24 Business | Garth Theunissen | SENS needs fixing, but the JSE disagrees

Subscribers can listen to this article The JSE building in Sandton. (Fivepointsix/Getty) While the JSE has made efforts to simplify its listing requirements, little evidence of this can be seen in many an indecipherable regulatory announcement. Given the plethora of scandals involving JSE-listed companies in recent years, perhaps it's time to consider some plainer language

Business insolvency filings highest in years

Watch: Filings hit highest number since 2019 in 2023 Published Mar 24, 2024  •  Last updated Mar 24, 2024  •  1 minute read A 'closed' sign hangs in a store window in Ottawa. Photo by Adrian Wyld/The Canadian Press files Dina Kovacevic, editor-in-chief of Insolvency Insider Canada, talks with Financial Post’s Larysa Harapyn about the